27 - 29 May, 2026
Congress CenterBasel Switzerland Ugur Eskiocak, Ph.DCEO at Voro TherapeuticsSpeaker
Profile
Ugur Eskiocak, PhD is the Co-founder and CEO of Voro Therapeutics. Voro is developing oncology therapeutics through its category-defining, tumor-activated biologics platform. He has 20 years of experience in oncology research and drug development. He has advanced 6 immuno-oncology programs through IND-enabling studies and into the clinical trials in various leadership roles at Compass Therapeutics, Xilio Therapeutics, Takeda and Janux Therapeutics.
Agenda Sessions
Tumor-activated PrimeBody Biologics Platform Enables Safe and Efficacious CD47 Targeting with Superior Therapeutic Index in Preclinical Models
, 14:15View Session